stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) Return on assets
Perrigo Company plc's return on assets over the twelve months to 30 September 2026 was −20.2%, down 4.5 percentage points from fiscal 2025 (−15.7%). Over the past ten years it has ranged from −24.2% (fiscal 2016) to 1.31% (fiscal 2019); the current reading is higher than 17% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −15.7% | (14.00) |
| FY2024 | −1.68% | (1.56) |
| FY2023 | −0.12% | 1.19 |
| FY2022 | −1.31% | (0.68) |
| FY2021 | −0.63% | 0.80 |
| FY2020 | −1.43% | (2.74) |
| FY2019 | 1.31% | 0.15 |
| FY2018 | 1.16% | 0.22 |
| FY2017 | 0.94% | 25.10 |
| FY2016 | −24.2% | (24.38) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | 7.85% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.64% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc | −20.2% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on PRGO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement